VIDEO: Weng discusses impact of Protocol W on NPDR treatment

ByChristina Y. Weng, MD, MBA, FASRS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WAILEA, Hawaii — In this video from Retina 2021, Christina Y. Weng, MD, MBA, discusses the impact of the recent DRCR Retina Network Protocol W, looking at the treatment of moderate to severe nonproliferative diabetic retinopathy with aflibercept.

Published by:

Sources/Disclosures

Collapse

Source:

Christina Y. Weng, MD, MBA

Read more about

nonproliferative diabetic retinopathy

aflibercept

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment